Singapore markets open in 8 hours 58 minutes

Ascendis Pharma A/S (ASND)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
134.85-2.35 (-1.71%)
As of 12:01PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close137.20
Open138.36
Bid134.11 x 100
Ask135.96 x 100
Day's range133.53 - 138.36
52-week range83.75 - 161.00
Volume128,811
Avg. volume335,876
Market cap7.634B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-9.51
Earnings date02 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est180.47
  • Insider Monkey

    Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript

    Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript May 4, 2024 Ascendis Pharma A/S isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to the Q1 2024 Ascendis Pharma Earnings Conference Call. At this time, all […]

  • Simply Wall St.

    Ascendis Pharma First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

    Ascendis Pharma ( NASDAQ:ASND ) First Quarter 2024 Results Key Financial Results Revenue: €95.9m (up 186% from 1Q...

  • GlobeNewswire

    Ascendis Pharma Reports First Quarter 2024 Financial Results

    — Rollout of YORVIPATH® initiated in Germany and Austria, with an estimated 55 doctors writing prescriptions and ~100 patients receiving commercial product as of March 31 — TransCon™ PTH (palopegteriparatide) PDUFA date of May 14, 2024, for adults with hypoparathyroidism. If approved, U.S. launch planned in Q3 — TransCon CNP (navepegritide) pivotal ApproaCH Trial on track for topline results in Q4 2024 — SKYTROFA® Q1 revenue more than doubled year-over-year to €65 million; Q1 operating expenses